10-Q: Hong Yuan Holding Group Reports Minimal Activity in Q3 2024, Continues Search for Acquisitions

Sentiment:

Quarterly Report 12 November 2024 4:27 PM

📋All filings for Hong Yuan Holding Group

Hong Yuan Holding Group reports minimal financial activity for the third quarter of 2024, with ongoing efforts to identify potential acquisition targets.

Capital raiseThe company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.The company plans to seek additional debt and/or equity financing to sustain its operations.The company's CEO and principal shareholder, Mr. Xudong, would favorably entertain funding, through loans, corporate expenses for approximately 24 months.

Worse than expectedThe company reported no revenue and a net loss, indicating worse than expected financial performance.The company's accumulated deficit and working capital deficit have increased, further indicating worse than expected financial health.The auditor's going concern qualification raises significant doubts about the company's ability to continue operations, which is worse than expected.

Summary

Hong Yuan Holding Group, a development stage company, has released its financial results for the quarter ended September 30, 2024.
The company reported no revenue for both the three and nine-month periods ending September 30, 2024 and 2023.
Operating expenses for the three months ended September 30, 2024 were $5,495, a decrease from $10,166 in the same period of 2023.
The net loss for the three months ended September 30, 2024 was $5,495, compared to a net loss of $10,166 for the same period in 2023.
For the nine months ended September 30, 2024, operating expenses were $31,189, slightly down from $31,419 in 2023.
The net loss for the nine months ended September 30, 2024 was $31,189, compared to a net loss of $31,419 for the same period in 2023.
The company's accumulated deficit stands at $97,448,110 as of September 30, 2024.
The company has a working capital deficit of $182,433 as of September 30, 2024.
The company is actively seeking potential acquisitions in China.
The company's operations are primarily funded by its CEO and major shareholder.

Sentiment

Score: 2

Explanation: The document paints a bleak picture of the company's financial health, with no revenue, significant losses, a going concern qualification, and reliance on a single funding source. The company's future is highly uncertain, and the sentiment is therefore very negative.

Positives

Operating expenses decreased by 45.9% for the three months ended September 30, 2024, compared to the same period in 2023.
The net loss for the three months ended September 30, 2024 was lower than the same period in 2023.
The company is actively pursuing potential acquisitions, which could lead to future growth.

Negatives

The company has not generated any revenue for the three and nine months ended September 30, 2024.
The company has an accumulated deficit of $97,448,110.
The company has a working capital deficit of $182,433.
The company's operations are primarily funded by its CEO and major shareholder, indicating a reliance on a single source of funding.
The company's auditors have expressed a going concern opinion, raising doubts about its ability to continue as a going concern.

Risks

The company's lack of revenue generation poses a significant risk to its financial stability.
The company's reliance on debt and equity financing to fund its operations makes it vulnerable to market conditions and investor sentiment.
The company's ability to continue as a going concern is uncertain, as indicated by the auditor's opinion.
The company's acquisition strategy is subject to risks associated with cross-border business and the uncertainty of finding suitable targets.
The company's dependence on its CEO and major shareholder for funding creates a risk if this funding source becomes unavailable.

Future Outlook

The company plans to continue seeking potential acquisitions in China and is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect. The company anticipates incurring losses in the foreseeable future.

Management Comments

Management believes the Company will continue to incur losses and negative cash flows from operating activities for the foreseeable future.
Management plans to seek additional debt and/or equity financing for the Company but cannot assure that such financing will be available on acceptable terms.
The management has approached several companies in China and met the management of potential acquisition targets.
The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.

Industry Context

The company's focus on acquisitions in China reflects a broader trend of companies seeking growth opportunities in emerging markets. However, the challenges of cross-border business and the company's current financial situation present significant hurdles.

Comparison to Industry Standards

It is difficult to compare Hong Yuan Holding Group to industry standards due to its development stage and lack of revenue.
Many development stage companies in the biotech or tech sectors often have high burn rates and negative cash flows while they are developing their products or services.
The company's lack of revenue and reliance on a single funding source is not uncommon for early-stage companies, but the going concern qualification from the auditors is a significant concern.
Companies like Cassava Sciences (SAVA) or Amylyx Pharmaceuticals (AMLX) are examples of development stage companies that have experienced significant volatility and uncertainty in their early stages, but they have also had significant funding and research progress.
Hong Yuan Holding Group's situation is more precarious due to the lack of revenue and the going concern qualification, which is not typical for companies that have secured significant funding.

Related Party Transactions

During the nine months ended September 30, 2024, the company's current majority shareholder advanced $31,218 to the company as working capital.
As of September 30, 2024, the company owed its current majority shareholders $181,393.

Stakeholder Impact

Shareholders face significant risk due to the company's poor financial performance and going concern qualification.
Employees may be impacted by the company's financial instability and uncertain future.
Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

The company plans to continue seeking potential acquisitions in China.
The company will continue efforts to raise additional funding.
The company will continue to operate with the support of its CEO and major shareholder.

Key Dates

Date	Description
2001-09-29	Company incorporated in Nevada as Biocorp North America Inc.
2004-07-19	Company changed its name to Nat-UR, Inc.
2005-03-18	Company changed its name to Cereplast, Inc.
2013-04-05	Shareholders approved a 1-for-50 reverse stock split.
2014-01-31	Board of Directors approved a 1-for-50 reverse stock split.
2014-02-10	Company filed for Chapter 11 bankruptcy.
2014-02-14	Company filed a motion to convert Chapter 11 to Chapter 7 bankruptcy.
2014-02-21	Reverse stock split became effective.
2014-03-27	Chapter 11 bankruptcy converted to Chapter 7.
2019-03-22	Custodian Ventures, LLC appointed as custodian for Cereplast, Inc.
2019-06-04	Company filed a certificate of revival with the state of Nevada.
2019-10-04	Company issued 50,000,000 shares of common stock to Custodian Ventures, LLC.
2020-04-14	Custodian Ventures converted Series A preferred stock into common stock.
2020-04-15	Board approved the withdrawal of the certificate of designation of Series A Preferred stock.
2020-05-01	Company created 5,000,000 shares of series A-1 preferred stock.
2020-05-04	Company issued 5,000,000 shares of Series A-1 Preferred stock to Custodian Ventures LLC.
2020-11-03	Change of control completed with sale of shares to Xudong Li.
2020-11-18	Company changed its name to Hong Yuan Holding Group.
2023-09-30	End of the comparative period for the quarterly report.
2023-12-31	End of the fiscal year for comparative balance sheet data.
2024-09-30	End of the reporting period for the quarterly report.
2024-11-04	Latest practicable date for share count.
2024-11-12	Date of the report.

Keywords

acquisitions, development stage, financial results, operating expenses, net loss, going concern, working capital, China, funding, shareholder

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.